Carlson College of Veterinary Medicine

B. Lebleu, Moulton, H. M., Abes, R., Ivanova, G. D., Abes, S., Stein, D. A., Iversen, P. L., Arzumanov, A. A., and Gait, M. J., “Cell penetrating peptide conjugates of steric block oligonucleotides.”, Advanced drug delivery reviews, vol. 60, no. 4-5, pp. 517-29, 2008.

M. McPhillie, Zhou, Y., Bissati, K. El, Dubey, J., Lorenzi, H., Capper, M., Lukens, A. K., Hickman, M., Muench, S., Verma, S. Kumar, Weber, C. R., Wheeler, K., Gordon, J., Sanders, J., Moulton, H. M., Wang, K., Kim, T. - K., He, Y., Santos, T., Woods, S., Lee, P., Donkin, D., Kim, E., Fraczek, L., Lykins, J., Esaa, F., Alibana-Clouser, F., Dovgin, S., Weiss, L., Brasseur, G., Wirth, D., Kent, M. L., Hood, L., Meunieur, B., Roberts, C. W., S Hasnain, S., Antonyuk, S. V., Fishwick, C., and McLeod, R., “Author Correction: New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.”, Sci Rep, vol. 10, no. 1, p. 5512, 2020.

M. H. Nelson, Stein, D. A., Kroeker, A. D., Hatlevig, S. A., Iversen, P. L., and Moulton, H. M., “Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.”, Bioconjugate chemistry, vol. 16, no. 4, pp. 959-66, 2005.

H. M. Moulton and Moulton, J. D., “Arginine-rich cell-penetrating peptides with uncharged antisense oligomers.”, Drug discovery today, vol. 9, no. 20, p. 870, 2004.

N. B. Marshall, Oda, S. K., London, C. A., Moulton, H. M., Iversen, P. L., Kerkvliet, N. I., and Mourich, D. V., “Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.”, Journal of immunological methods, vol. 325, no. 1-2, pp. 114-26, 2007.

R. Abes, Arzumanov, A., Moulton, H. M., Abes, S., Ivanova, G., Gait, M. J., Iversen, P., and Lebleu, B., “Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides.”, Journal of peptide science : an official publication of the European Peptide Society, vol. 14, no. 4, pp. 455-60, 2008.

R. Burrer, Neuman, B. W., Ting, J. P. C., Stein, D. A., Moulton, H. M., Iversen, P. L., Kuhn, P., and Buchmeier, M. J., “Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models.”, Journal of virology, vol. 81, no. 11, pp. 5637-48, 2007.

G. McClorey, Moulton, H. M., Iversen, P. L., Fletcher, S., and Wilton, S. D., “Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.”, Gene therapy, vol. 13, no. 19, pp. 1373-81, 2006.

B. W. Neuman, Stein, D. A., Kroeker, A. D., Paulino, A. D., Moulton, H. M., Iversen, P. L., and Buchmeier, M. J., “Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.”, Journal of virology, vol. 78, no. 11, pp. 5891-9, 2004.

X. Gao, Ran, N., Dong, X., Zuo, B., Yang, R., Zhou, Q., Moulton, H. M., Seow, Y., and Yin, H., “Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy.”, Sci Transl Med, vol. 10, no. 444, 2018.

H. M. Moulton, Yoshihara, P. H., Mason, D. H., Iversen, P. L., and Triozzi, P. L., “Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.”, Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 8, no. 7, pp. 2044-51, 2002.